In vivo, in vitro and in silico methods for small molecule transfer across the BBB

Journal of Pharmaceutical Sciences

Volumn 98, Issue 12, 2009, Pages 4429-4468

  Mensch, Jurgen ^a   Oyarzabal, Julen ^b   Mackie, Claire ^a   Augustijns, Patrick ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Active transport; Blood brain barrier; CNS; Drug discovery; In silico modeling; In vitro model; In vivo model; Molecular descriptors; Passive diffusion; Permeability

Indexed keywords

ACTIVE TRANSPORT; ARTIFICIAL MEMBRANE; AUTORADIOGRAPHY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN PERFUSION; CAPILLARY ENDOTHELIUM; CELL STRAIN; CHROMATOGRAPHY; COMPUTER MODEL; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SUPPORT VECTOR MACHINE;

EID: 71649107843     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21745     Document Type: Article

References (316)

1. Miller G. 2000. Breaking down barriers. Science 297:1116-1118.
2. Reese TS, Karnovsky MJ. 1967. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207-217.
3. Brightman MW, Reese TS. 1969. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 40:648-677.
4. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G. 1991. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res Brain Res Rev 16:65-82.
5. Brownlees J, Williams CH. 1993. Peptidases, peptides, and the mammalian blood-brain barrier. J Neurochem 60:793-803. (Pubitemid 23066696)
6. Brownson EA, Abbruscato TJ, Gillespie TJ, Hruby VJ, Davis TP. 1994. Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J Pharmacol Exp Ther 270:675-680.
7. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci 86:695-698. (Pubitemid 19037807)
8. Krämer SD, Abbott NJ, Begley DJ. 2001. Biological models to study blood-brain barrier permeation. In: Testa B, van de Waterbeemd H, Folkers G, Guy R, editors. Pharmacokinetic optimization in drug research: Biological, physicochemical and computational strategies. Wiley-VCH: Weinheim. pp. 127-153.
9. Deguchi Y, Nozawa K, Yamada S, Yokoyama Y, Kimura R. 1997. Quantitative evaluation of brain distribution and blood-brain barrier efflux transport of probenecid in rats by microdialysis: Possible involvement of the monocarboxylic acid transport system. J Pharmacol Exp Ther 290:551-560. (Pubitemid 27171312)
10. Sun H, Miller DW, Elmquist WF. 2001. Effect of probenecid on fluorescein transport in the central nervous system using in-vitro and in-vivo models. Pharm Res 18:1542-1549. (Pubitemid 33022409)
11. Takanaga H, Murakami H, Koyabu N, Matsuo H, Naito M, Tsuruo T, Sawada Y. 1998. Efflux transport of tolbutamide across the blood-brain barrier. J Pharm Pharmacol 50:1027-1033. (Pubitemid 28464089)
12. Bentz J, Tran TT, Polli JW, Ayrton A, Ellens H. 2005. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. Pharm Res 22:1667-1677. (Pubitemid 41355906)
13. Gao B, Stieger B, Noé B, Fritschy JM, Meier PJ. 1999. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1263. (Pubitemid 29455921)
14. Cisternino S, Rousselle C, Lorico A, Rappa G, Scherrmann JM. 2003. Apparent lack of mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharm Res 20:904-909. (Pubitemid 36628438)
15. Eisenblätter T, Galla HJ. 2002. A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 293:1273-1278. (Pubitemid 34681079)
16. Cisternino S, Mercier C, Bourasset F, Rouse F, Scherrmann JM. 2004. Expression, upregulation, and tranport activity of the multidrug-resistance protein Abcg2 at the mouse blood brain barrier. Cancer Res 64:3296-3301. (Pubitemid 38581436)
17. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH. 2005. The effect of Bcrp1 (Abcg2) on the in-vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
18. Dobson PD, Kell DB. 2008. Carrier-mediated cellular uptake of pharmaceutical drugs: An exception or the rule? Nat Rev Drug Discov 7:205-220.
19. Lee G, Dallas S, Hong M, Bendayan R. 2001. Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations. Pharmacol Rev 53:569-596. (Pubitemid 33136238)
20. Liu X, Chen C, Smith BJ. 2008. Progress in brain penetration in drug discovery and development. J Pharmacol Exp Ther 325:349-356. (Pubitemid 351574780)
21. Pardridge WM. 2001. Crossing the blood-brain barrier: Are we getting it right? Drug Discov Today 6:1-2.
22. Pardridge WM. 2002. William Pardridge discusses the lack of BBB research. Interview by Rebecca N. Lawrence. Drug Discov Today 7:223-226.
23. Metting TL, Burgio DE, Terry AV Jr, Beach JW, McCurdy CR, Allen DD. 1998. Inhibition of brain choline uptake by isoarecolone and lobeline derivatives: Implications for potential vector-mediated brain drug delivery. Neurosci Lett 258:25-28.
24. Geldenhuys WJ, Lockman PR, Philip AE, McAfee JH, Miller BL, McCurdy CR, Allen DD. 2005. Inhibition of choline uptake by N-cyclohexylcholine, a high affinity ligand for the choline transporter at the blood brain barrier. J Drug Target 13:259-266.
25. Pardridge WM. 2007. Blood-brain barrier delivery. Drug Discov Today 12:54-61.
26. Fortin D, Gendron C, Boudrias M, Garant MP. 2007. Enhanced chemotherapy delivery by intraarterial infusion and blood- brain barrier disruption in the treatment of cerebral metastasis. Cancer 109:751-760. (Pubitemid 46233237)
27. Ferguson S, Lesniak MS. 2007. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Current Drug Deliv 4:169-180. (Pubitemid 46557493)
28. Pardridge WM. 1999. Blood-brain barrier biology and methodology. J Neurovirol 5:556-569.
29. Kalvass JC, Maurer TS. 2002. Influence of non-specific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharm Drug Disp 23:327-338.
30. Abbott NJ. 2004. Prediction of blood-brain barrier permeation in drug discovery from in-vivo, in-vitro and in-silico models. DDT Technol 1:407-416.
31. Reichel A, 2006. The role of blood-brain barrier studies in the Pharmaceutical industry. Curr Drug Metabolism 7:183-203.
32. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CECA, Kasman IN, LaPerle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc Mark, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C. 2005. The impact of P-Glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Disp 33:165-174. (Pubitemid 40023528)
33. Bourasset F. 2005. Neuropharmacokinetics of a new alpha -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide], in the rat. Drug Metab Disp 33:1137-1143.
34. Van de Waterbeemd H, Smith DA, Jones BC. 2001. Lipophilicity in PK design: Methyl, ethyl, futile. J Comput Aided Mol Des 15:273-286.
35. Jeffrey P, Summerfield SG. 2007. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 37:1135-1151. (Pubitemid 350041554)
36. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. 2008. On the rate and extent of drug delivery to the brain. Pharm Res 25:1737-1750.
37. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. 2006. Brain distribution of cetirizine enantiomers: Comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u) and K(p,uu). Drug Metab Dispos 34:318-323.
38. Boström E, Simonsson USH, Hammarlund-Udenaes M. 2006. In vivo blood-brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34:1624-1631.
39. Maurer TS, DeBartolo DB, Tess DA, Scott DO. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
40. Liu X, Smith BJ, Chen C, Callegari E, Becker L, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, van Deusen J. 2005. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: An experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther 313:1254-1262. (Pubitemid 40727030)
41. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang ST, Hersey A, Spalding DJ, Jeffrey P. 2006. Improving the in vitro prediction of in vivo CNS penetration: Integrating permeability, Pgp efflux and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290. (Pubitemid 43345304)
42. Kalvass JC, Maurer TS, Pollack GM. 2007. Use of plasma and brain unbound fractions to assess the extent of braindistribution of 34 drugs: Comparison of unbound concentration ratios to P-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666.
43. Oldendorf WH. 1970. Measurement of brain uptake of radiolabeled substances using tritiated water internal standard. Brain Res 24:372-376.
44. Oldendorf WH. 1981. Clearance of radiolabeled substances by brain after arterial injection using a diffusible internal standard. In: Marks N, Rodnight R, editors. Researh methods in neurochemistry. New York: Plenum Publishing Co. pp. 91-1121.
45. Bonate PL. 1995. Animal models for studying transport across the blood-brain barrier. J Neurosci Methods 56:1-15.
46. Pardridge WM, Fierer G. 1985. Blood-brain barrier transport of butanol and water relative to Nisopropyl-p-[I] iodoamphetamine (IMP) as the internal reference. J Cereh Blood Flow Metab 5:275-281. (Pubitemid 15123214)
47. Pardridge WM.1995. Transport of small molecules through the blood-brain barrier: Biology and methodology. Adv Drug Deliv 15:5-36.
48. Kety SS. 1951. The theory and applications of the exchange in inert gas at the lungs and tissues. Pharmacol Rev 3:1-41.
49. Renkin EM. 1959. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. 1700. Am J Physiol 197:1205-1210.
50. Crone C. 1963. Permeability of capillaries in various organs as determined by use of the 'indicator diffusion' method. Acta Physiol Scand 58:292-305.
51. Takasato Y, Rapoport SI, Smith QR. 1984. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol (Lond) 247:H484-H493. (Pubitemid 14047362)
52. Zlokovic BV, Begley DJ, Djuricic BM, Mitrovic DM. 1986. Measurement of solute transport across the blood-brain barrier in the perfused guinea pig brain: Method and application to N-methyl-aminoisobutyric acid. J Neurochem 46:1444-1451.
53. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. 2000. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-386. (Pubitemid 30108457)
54. Smith QR, Allen DD. 2003. In situ brain perfusion technique. Methods Mol Med 89:209-218.
55. Triguero D, Buciak J, Pardridge WM. 1990. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54:1882-1888. (Pubitemid 20173337)
56. Murakami H, Takanaga H, Matsuo H, Ohtani H, Sawada Y. 2000. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol 279:1022-1028.
57. Cisternino S, Rousselle C, Dagenais C, Scherrmann JM. 2001. Screening of multidrug-resistance sensitive drugs by in-situ brain perfusion in P-glycoprotein-deficient mice. Pharm Res 18:183-190. (Pubitemid 32592598)
58. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. 2007. Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205. (Pubitemid 46956363)
59. Doan KH, Wring SH, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkinson KK, Polli JW. 2004. Steady-state brain concentration of antihistamines in rats: Interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. Pharmacology 72: 92-998. (Pubitemid 39179257)
60. Ohno K, Pettigrew KD, Rapoport SI. 1978. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol (Lond) 235:299-307. (Pubitemid 9159902)
61. Brodie BB, Kurz H, Schanker LS. 1960. The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 130:20-25.
62. Patlak CS, Blasberg RG, Fenstermacher JD. 1983. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1-7.
63. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897.
64. 14C]-antipyrine. Am J Physiol 234:H59.
65. Fenstermacher JD, Blasberg R, Patlak C. 1986. Membrane transport of antineoplastic agents. In: Goldmann ID, editor. The international encyclopedia of pharmacology and pharmacotherapeutics. Oxford: Pergamon Press. p. 113.
66. Fenstermacher JD, Wei L. 1998. Measuring local cerebral capillary permeability-surface area products by quantitative autoradiography. In: Pardridge WM, editor. Introduction to the blood-brain barrier: Methodology, biology and pathology. Cambridge, UK: Cambridge University Press. pp. 122-132.
67. Elmquist WF, Sawchuck RJ. 1997. Application of microdialysis in pharmacokinetic studies. Pharm Res 14:267-288.
68. de Lange ECM, de Boer AG, Breimer DD. 2000. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliver Rev 45:125-148.
69. Feng MR. 2002. Assessment of blood-brain barrier penetration: In-silico, in-vitro and in-vivo. Current Drug Metabolism 3:647-657.
70. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. 2003. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092. (Pubitemid 36254421)
71. de Lange ECM, de Boer AG, Breimer DD. 1999. Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 36:211-227.
72. Terasaki T, Deguchi Y, Kasama Y, Pardridge WM, Tsuji A. 1992. Determination of in-vivo steadystate unbound drug concentration in the brain interstitial fluid by microdialysis. Int J Pharm 81:143-152.
73. Lindefors N, Amberg G, Ungerstedt U. 1989. Intracerebral microdialysis. I. Experimental studies of diffusion kinetics. J Pharmacol Meth 22:141-156. (Pubitemid 19275442)
74. Amberg G, Lindefors N. 1989. Intracerebral microdialysis. II. Mathematical studies of diffusion kinetics. J Pharmacol Meth 22:157-183. (Pubitemid 19275443)
75. Bungay PM, Morrison PF, Dedrick RL. 1990. Steady-state theory for quantitative microdialysis of solutes and water in-vivo and in-vitro. Life Sci 46:105-119.
76. Morrison PF, Bungay PM, Hsiao JK, Ball BA, Mefford IN, Dedrick RL. 1991. Quantitative microdialysis: Analysis of transient and application to pharmacokinetics in brain. J Neurochem 57:103-119.
77. Lonnroth P, Jansson PA, Smith U. 1987. A microdialysis method allowing characterization of intracellular water space in humans. Am J Physiol 253:E228-E231. (Pubitemid 17155220)
78. de Lange ECM, Danhof M, de Boer AG, Breimer DD. 1997. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier Brain research. Brain Res Rev 25:27-49. (Pubitemid 27459719)
79. Wong SL, Wang Y, Sawchuck RJ. 1992. Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis. Pharm Res 9:332-338.
80. Wang Y, Wong SL, Sawchuck RJ. 1991. Comparison of in-vitro and in-vivo calibration of microdialysis probes using retrodialysis. Curr Sep 10:87.
81. Dishino DD, Welch MJ, Kilbourn MR, Raichle ME. 1983. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 24:1030-1038.
82. Josserand V, Pelerin H, de Bruin B, Jego B, Kuhnast B, Hinnen F, Duconge F, Boisgard R, Beuvon F, Chassoux F, Daumas-Duport C, Ezan E, Dolle F, Mabondzo A, Tavitian B. 2006. Evaluation of drug penetration into the brain: A double study by in-vivo imaging with positron emission tomography and using an in-vitro model of the human blood-brain barrier. JPET 316:79-86. (Pubitemid 41832583)
83. Brooks DJ, Beaney RP, Lammertsma AA, Leenders KL, Horlock PL, Kensett MJ, Marshall J, Thomas DG, Jones T. 1984. Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. J Cereb Blood Flow Metab 4:535-545. (Pubitemid 15222298)
84. Schlageter NL, Carson RE, Rapoport SI. 1987. Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography. J Cereb Blood Flow Metab 7:1-8.
85. Huang SC, Hoh C, Barrio JR, Phelps ME. 1998. Measurement of blood brain barrier permeability in humans with positron emission tomography. In: Pardridge WM, editor. Introduction to the blood-brain barrier: Methodology, biology and pathology. Cambridge, UK: Cambridge University Press. pp. 122-146.
86. Bickel U. 2005. How to measure drug transport across the blood-brain barrier. NeuroRx J Am Soc Exp Neuro Ther 2:15-26.
87. Dingemanse J, Sollie F, Breimer D, Danhof MJ. 1988. Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. Pharmacok Biopharm 16:203-228.
88. Hilbert J, Battista D. 1991. Quazepam and flurazepam: Differential pharmacokinetic and pharmacodynamic characteristics. J Clin Psychiatry 52: 21-26.
89. Caccia S, Carli M, Garattini S, Poggesi E, Rech R, Samanin R. 1980. Pharmacological activities of clobazam and diazepam in the rat: Relation to drug brain levels. Arch Int Pharmacodyn 243:275-283.
90. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. 2005. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin pharmacol Ther 77:503-514. (Pubitemid 40824964)
91. Schmidt KC, Turkheimer FE. 2002. Kinetic modeling in positron emission tomography. Q J Nucl Med 46:70-85. (Pubitemid 34808740)
92. Ewing JR, Knight R, Nagaraja TN, Yee JS, Nagesh V, Whitton PA, Li L, Fenstermacher JD. 2003. Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn Reson Med 50:283-292. (Pubitemid 36950847)
93. Patlak CS, Blasberg RG, Fenstermacher JD. 1983. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1-7.
94. Ewing JR, Knight R, Nagaraja TN, Yee JS, Nagesh V, Whitton PA, Li L, Fenstermacher JD. 2003. Patlak plots of Gd-DTPA MRI data yield blood-brain transfer constants concordant with those of 14C-sucrose in areas of blood-brain opening. Magn Reson Med 50:283-292. (Pubitemid 36950847)
95. Reichel A, Begley DJ, Abbott NJ. 2003. An overview of in-vitro techniques for blood-brain barrier studies. From Methods in Molecular Medicine. Blood-Brain Barrier Biol Res Protoc 89:307-324.
96. Gumbleton M, Audus KL. 2001. Progress and limitations in the use of in-vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 90:1681-1698. (Pubitemid 33062590)
97. Lundquist S, Renftel M. 2002. The use of in-vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry-Background and current status in the drug discovery process. Vascul Pharmacol 38:355-364. (Pubitemid 36398257)
98. Joo F. 1985. The blood-brain barrier in-vitro: Ten years of research on microvessels isolated from the brain. Neurochem Int 7:1-25. (Pubitemid 15145347)
99. Pardridge WM. 1998. Isolated brain capillaries: an in-vitro model of blood-brain barrier research. In: Pardridge WM, editor. Introduction to the blood-Brain Barrier: Methodology, Biology, and pathology. Cambridge: Cambridge University Press. p. 49-61.
100. de Boer AG, Gaillard PJ. 2002. In-vitro models of the blood-brain barrier: When to use which? Curr Med Chem Central Nerv Syst Agents 2:203-209.
101. Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer V, Duhem C, Lundquist S, Rentfel M, Torpier G, Dehouck MP. 1999. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev 36:165-178.
102. Dehouck MP, Meresse S, Delorme P, Fruchart JC, Cecchelli R. 1990. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem 54:1798-1801. (Pubitemid 20136746)
103. Gaillard PJ, Voorwinden LHH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD. 2001. Establishment and functional characterization of an in-vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci 12:215-222.
104. Audus KL, Borchardt RT. 1986. Characterization of an in-vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm Res 3:81-87.
105. Audus KL, Rose JM, Wang W, Borchardt RT. 1998. Brain microvessel endothelial cell culture systems. In: Pardridge WM, editor. An introduction to the blood-brain barrier: Methodology and biology. New York: Cambridge University Press. pp. 86-93.
106. Lasbennes F, Gayet J. 1984. Capacity for energy metabolism in microvessels isolated from rat brain. Neurochem Res 9:1-10. (Pubitemid 14172270)
107. Nicolazzo JA, Charman SA, Charman WN. 2006. Methods to assess drug permeability across the blood-brain barrier. J Pharm Pharmacol 58:281-293.
108. Pardridge WM. 2004. Holy grails and in-vitro blood-brain barrier models. Drug Discov Today 9:258. (Pubitemid 38328509)
109. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, Lindmark T, Mabondzo A, Nilsson JE, Raub TJ, Stanimirovic D, Terasaki T, Oeberg JO, Oesterberg T. 2005. In-vitro models for the blood-brain barrier. Toxicol In Vitro 19:299-334.
110. Zhang Y, Li CSW, Ye Y, Johnson K, Poe J, Johnson S, Bobrowski W, Garrido R, Madhu C. 2006. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Drug Metab Dispos 34:1935-1943. (Pubitemid 44771724)
111. Pardridge WM. 1998. Isolated brain capillaries: an in-vitro model of blood-brain barrier research. In: De Boer AG, Sutanto W, editors. Drug Transport across the Blood-Brain Barrier: Amsterdam: Harwood. p. 5-16.
112. Bowman PD, Ennis SR, Rarey KE, Betz AL, Goldstein GW. 1983. Brain microvessel endothelial cells in tissue culture: A model for study of blood-brain barrier permeability. Ann Neurol 14:396-402.
113. Audus KL, Borchardt RT. 1987. Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann NY Acad Sci 507:9-18.
114. Audus KL, Ng L, Wang W, Borchardt RT. 1996. Brain microvessel endothelial cell culture systems. In: Borchardt RT, Smith PL, Wilson G, editors. Models for assessing drug absorption and metabolism. New York: Plenum Press. pp. 239-258.
115. Miller DW, Audus KL, Borchardt RT. 1992. Application of cultured endothelial cells of the brain microvasculature in the study of the blood-brain barrier. J Tiss Cult Meth 14:217-224.
116. Bao J, Liu G, Xu Q. 2004. Effect of cyclosporin A and tetrandrine on rhodamine 123 accumulation in bovine brain capillary endothelial cells. Zhongguo Yaolixue Tongbao 20:1265-1268. (Pubitemid 40260573)
117. Lundquist S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. 2002. Prediction of drug transport through the blood-brain barrier in-vivo: A comparison between two in-vitro cell models. Pharm Res 19:976-981. (Pubitemid 34804239)
118. Raub TJ, Kuentzel SL, Sawada GA. 1992. Permeability of bovine brain microvessel endothelial cells in-vitro: Barrier tightening by a factor released from astroglioma cells. Exp Cell Res 199:330-340.
119. Eddy EP, Maleef BE, Hart TK, Smith PL. 1997. In vitro models to predict blood-brain barrier permeability. Adv Drug Deliver Rev 23:185-198.
120. Glynn SL, Yazdanian M. 1998. In-vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agent. J Pharm Sci 87:306-310. (Pubitemid 28204583)
121. Polli JW, Humphreys JE, Wring SA, Burnette TC, Read KD, Hersey A, Butina D, Bertolotti L, Pugnaghi F, Serbjit-Singh J. 2000. A comparison of Madin-Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery. In: Balls M, Zeller AM, Halder M, editors. Progress in the reduction, renement and replacement of animal experimentation. Amsterdam: Elsevier Sciences. pp. 271-289.
122. Rochat B, Baumann P, Audus KL. 1999. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831:229-236. (Pubitemid 29336205)
123. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 2005. Quantitative assessment of HIV-1 protease inhibitor inter-interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 22:1259-1268.
124. Pardridge WM, Triguero D, Yang J, Cancilla PA. 1990. Comparison of in-vitro and in-vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 253:884-891. (Pubitemid 20181741)
125. Tao-Cheng JH, Nagy Z, Brightman MW. 1987. Tight junctions of brain endothelium in-vitro are enhanced by astroglia. J Neurosci Neurosci 7:3293-3299.
126. Gaillard PJ, van der Sandt ICJ, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD. 2000. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res 17:1198-1205.
127. Sobue K, Yamamoto N, Yoneda K, Hodgson ME, Yamashiro K, Tsuruoka N, Tsuda T, Katsuya H, Miura Y, Asai K, Kato T. 1999. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res 35:155-164. (Pubitemid 29518406)
128. Abbruscato TJ, Davis TP. 1999. Protein expression of brain endothelial cell E-cadherin after hypoxia/aglycemia: Influence of astrocyte contact. Brain Res 842:277-286.
129. Isobe I, Watanabe T, Yotsuyanagi T, Hazemoto N, Yamagata K, Ueki T, Nakanishi K, Asai K, Kato T. 1996. Astrocytic contributions to blood-brain barrier (BBB) formation by endothelial cells: A possible use of aortic endothelial cell for in-vitro BBB model. Neurochem Int 28:523-533. (Pubitemid 26161323)
130. Gaillard PJ, de Boer AG. 2000. Relationship between permeability status of the blood-brain barrier and in-vitro permeability coefficient of a drug. Eur J Pharm Sci 12:95-102.
131. Raub TJ. 1996. Signal transduction and glial cell modulation of cultured brain microvessel endothelial cell tight junctions. Am J Physiol 271:C495-C503. (Pubitemid 26298909)
132. Wolburg H, Neuhaus J, Kniesel U, Krauss B, Schmid EM, Ocalan M, Farrell C, Risau W. 1994. Modulation of tight junction structure in blood-brain barrier endothelial cells: Effects of tissue culture, second messengers and cocultured astrocytes. J Cell Sci 107:1347-1357. (Pubitemid 24177334)
133. Hoheisel D, Nitz T, Franke H, Wegener J, Hakvoort A, Tilling T, Galla HJ. 1998. Hydrocortisone reinforces the blood-brain properties in a serum free cell culture system. Biochem Biophys Res Commun 247:312-315. (Pubitemid 28419944)
134. Franke H, Galla HJ, Beuckmann CT. 1999. An improved low permeability in-vitro model of the blood-brain barrier: Transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res 818:65-71. (Pubitemid 29227284)
135. Franke H, Galla H-J, Beuckmann CT. 2000. Primary cultures of brain microvessel endothelial cells: A valid and flexible model to study drug transport through the blood-brain barrier in-vitro. Brain Res Protoc 5:248-256. (Pubitemid 30440753)
136. Tewes B, Franke H, Hellwig S, Hoheisel D, Decker S, Griesche D, Tilling T, Wegener J, Galla HJ. 1997. Preparation of endothelial cells in primary cultures obtained from 6 month old pigs. In: de Boer AG, Sutanto W, editors. Transport across the blood brain barrier: In-vitro and in-vivo techniques. Amsterdam: Harwood Academic. pp. 91-97.
137. Kido Y, Tamai I, Nakanishi T, Kagami T, Hirosawa I, Sai Y, Tsuji A. 2002. Evaluation of blood-brain barrier transporters by co-culture of brain capillary endothelial cells with astrocytes. Drug Metab Pharmacokinet 17:34-41.
138. Reichel A, Begley DJ, Abbot NJ. 2000. Carrier-mediated delivery of metabotrophic glutamate receptor ligands to the central nervous system: Structural tolerance and potential of the L-system amino acid transporter at the blood-brain barrier. J Cereb Blood Flow Metab 20:168-174. (Pubitemid 30019842)
139. Begley DJ, Lechardeur D, Chen ZD, Rollinson C, Bardoul M, Roux F, Scherman D, Abbot NJ. 1996. Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4. J Neurochem 67:988-995. (Pubitemid 26277910)
140. Rist RJ, Romero IA, Chan MW, Couraud PO, Roux F, Abbot NJ. 1997. F-actin cytoskeleton and sucrose permeability of immortalised rat brain microvascular endothelial cell monolayers: Effects of cyclic AMP and astrocytic factors. Brain Res 768:10-18. (Pubitemid 27433471)
141. Neuhaus W, Lauer R, Oelzant S, Fringeli UP, Ecker GF, Noe CR. 2006. A novel flow based hollow-fiber blood-brain barrier in-vitro model with immortalised cell line PBMEC/C1-2. J Biotech 125:127-141. (Pubitemid 44066610)
142. Cucullo L, McAllister M, Kight K, Krizanac-Bengez L, Marroni M, Stanness K, Janigro D. 2002. A new dynamic in-vitro model for the multidimensional study of astrocyte-endothelial cell interactions at the blood-brain barrier. Brain Res 951:243-254. (Pubitemid 35248021)
143. Krizinac-Bengez L, Kapural M, Parkinson F, Cucullo L, Hossain M, Mayberg MR, Janigro D. 2003. Effects of transient loss of shear stress on blood-brain barrier endothelium: Role of nitric oxide and IL-6. Brain Res 977:239-246. (Pubitemid 36782480)
144. Ballermann BJ, Dardik A, Eng E, Liu A. 1998. Shear stress and the endothelium. Kidney Int Suppl 67:100-108.
145. Desai S, Marroni M, Cucullo L, Bengez L, Hossein M, Mayberg MR, Grant GA, Janigro D. Mechanisms of endothelial survival under shear stress. Endothelium 9:89-102.
146. Ott MJ, Olson JL, Ballermann BJ. 1995. Chronic in-vitro flow promotes ultrastructural differentiation of endothelial cells. Endothelium 3:21-30.
147. Pohlmann TH, Harlan JM. 2000. Adaptive responses of the endothelium to stress. J Surg Res 89:85-199.
148. Stanness KA, Westrum LE, Fornaciari E, Mascagni P, Nelson JA, Stenglein SG, Myers T, Janigro D. 1997. Morphological and functional characterisation of an in-vitro blood brain barrier model. Brain Res 771:329-342. (Pubitemid 27492111)
149. Stanness KA, Guatteo E, Janigro D. 1996. A dynamic model of the blood brain barrier invitro. Neurotoxicology 17:481-496. (Pubitemid 26321348)
150. Janigro D, Leaman SM, Stanness KA. 1999. Dynamic in-vitro modeling of the blood-brain barrier: A novel tool for studies of drug delivery to the brain. Pharm Sci Technol Today 2:7-12. (Pubitemid 29132899)
151. Cucullo L, Aumayr B, Rapp E, Janigro D. 2005. Drug delivery and in-vitro models of the blood-brain barrier. Curr Opin Drug Discov Dev 8:89-99. (Pubitemid 40116334)
152. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. 1988. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85:4486-4490. (Pubitemid 18177781)
153. Veronesi B. 1996. Characterization of the MDCK cell line for screening of neurotoxicants. Neurotoxicology 17:433-443. (Pubitemid 26321344)
154. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK, Serabjit-Singh CJ. 2003. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec1), a second-generation non-sedating antihistamine. J Pharm Sci 92:2082-2089.
155. Carrara S, Reali V, Misiano P, Dondio G, Bigogno C. 2007. Evaluation of in-vitro brain penetration: Optimized PAMPA and MDCKII-MDR1 assay comparison. Int J Pharm 345:125-133. (Pubitemid 350103647)
156. Madgula VLM, Avula B, Niranjan RVL, Khan IA, Khan SI. 2007. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: In-vitro models for intestinal and blood-brain barrier permeability. Planta Medica 73:330-335. (Pubitemid 46910414)
157. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ. 2005. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288:349-359. (Pubitemid 40038588)
158. Polli JW, Humphreys JE, Wring SA, Burnette TC, Read KD, Hersey A, Butina D, Bertolotti L, Pugnaghi F, Serbjit-Singh J. 2000. A comparison of Madin-Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery. In: Balls M, Zeller AM, Halder M, editors. Progress in the reduction, renement and replacement of animal experimentation. Amsterdam: Elsevier Sciences. pp. 271-289.
159. Hurst RD, Fritz IB. 1996. Properties of an immortalised vascular endothelial/glioma cell coculture model of the blood brain barrier. J Cell Physiol 167:81-88.
160. Hurst RD, Heales SJ, Dobbie MS, Barker JE, Clark JB. 1998. Decreased endothelial cell glutathione and increased sensitivity to oxidative stress in an in-vitro blood-brain barrier model system. Brain Res 802:232-240.
161. Kuchler-Bopp S, Delaunoy JP, Artault JC, Zaepfel M, Dietrich JB. 1999. Astrocytes induce several blood-brain barrier properties in non-neural endothelial cells. Neuroreport 10:1347-1353. (Pubitemid 29403721)
162. Scism JL, Laska DA, Horn JW, Gimple JL, Pratt SE, Shepard RL, Dantzig AH, Wrighton SA. 1999. Evaluation of an in-vitro coculture model for the blood-brain barrier: Comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources. In Vitro Cell Dev Biol Anim 35:580-592.
163. Ramsohoye PV, Fritz IB. 1998. Preliminary characterization of glial-secreted factors responsible for the induction of high electrical resistances across endothelial monolayers in a blood-brain barrier model. Neurochem Res 23:1545-1551.
164. Hubatsch I, Ragnarsson EGE, Artursson P. 2007. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nature Protoc 2:2111-2119. (Pubitemid 351565848)
165. Artursson P, Palm K, Luthman K. 1996. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliver Rev 22:67-84. (Pubitemid 26423598)
166. Masungi C, Borremans C, Willems B, Mensch J, van Dijck A, Augustijns P, Brewster ME, Noppe M. 2004. Usefulness of a novel Caco-2 cell perfusion system. I. In-vitro prediction of the absorption potential of passively diffused compounds. J Pharm Sci 93:2507-2521. (Pubitemid 39319434)
167. Yee S. 1997. In-vitro permeability across Caco-2 cells (colonic) can predict in-vivo (small intestinal) absorption in man - Fact or myth. Pharm Res 14:763-766. (Pubitemid 27281671)
168. Lohmann C, Huwel S, Galla HJ. 2002. Predicting blood-brain barrier permeability of drugs: Evaluation of different in-vitro assays. J Drug Target 10:263-276. (Pubitemid 34746308)
169. Pidgeon C, Ong S, Liu H, Qiu X, Pidgeon M, Dantzig AH, Munroe J, Hornback WJ, Kasher JS, Glunz L, Czereba TJ. 1995. IAM chromatography: An in-vitro screen for predicting drug membrane permeability. J Med Chem 38:590-594.
170. Stein WD. 1986. Transport and diffusion across cell membranes. Orlando, FL: Academic Press.
171. Ong S, Hanlan L, Pidgeon C. 1996. Immobilized-artificial-membrane chromatography: Measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 728:113-128. (Pubitemid 26146680)
172. Nasal A, Sznitowska M, Bucinski A, Kaliszan R. 1995. Hydrophobicity parameter from high-performance liquid chromatography on an immobilized artificial membrane column and its relationship to bioactivity. J Chromatogr A 692:83-89.
173. Marcello J, Eddy EP, Smith PL, Cheng HY, Mitchell RC, Lee P. 1996. Evaluation of immobilized artificial membrane technology to predict blood brain barrier permeability. Book of Abstracts, 211th ACS National Meeting, New Orleans, LA, March 24-28.
174. Reichel A, Begley DJ. 1998. Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm Res 15:1270-1274. (Pubitemid 28401720)
175. Stewart BH, Chan OH. 1998. Use of immobilized artificial membrane chromatography for drug transport applications. J Pharm Sci 87:1471-1478. (Pubitemid 28559627)
176. Sun J, Zhang TH, He ZG. 2005. Profiling drug membrane transport via immobilized artificial membrane. Curr Pharm Anal 1:273-282.
177. Salminen T, Pulli A, Taskinen J. 1997. Relationship between immobilized artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal 15:469-477. (Pubitemid 26384301)
178. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. 2003. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38:223-232. (Pubitemid 36349665)
179. Carrara S, Real V, Misiano P, Dondio G, Bigogno C. 2007. Evaluation of in-vitro brain penetration: Optimized PAMPA and MDCKII-MDR1 assay comparison. Int J Pharm 345:125-133. (Pubitemid 350103647)
180. Wexler DS, Gao L, Anderson F, Ow A, Nadasdi L, McAlorum A, Urfer R, Huang SG. 2005. Linking solubility and permeability assays for maximum throughput and reproducibility. J Biomol Screen 10:383-390. (Pubitemid 40800567)
181. Mensch J, Melis A, Mackie C, Mortishire-Smith R, Vanhoutte K, De Maesschalck R, Augustijns P, Brewster ME. 2007. Evaluation of a combined high throughput in-vitro permeability assay with in-silico P-gp estimations for the prediction of invivo logBB data. San Diego: Poster presentation AAPS.
182. Kerns EH, Di L, Petusky S, Farris M, Ley R, Jupp P. 2004. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J Pharm Sci 93:1440-1453. (Pubitemid 38725018)
183. Rose K, Hall L, Kier LB. 2002. Modeling blood-brain barrier partitioning using electrotopological state. J Chem Inf Comput Sci 42:651-666. (Pubitemid 35355274)
184. Martin I. 2004. Prediction of blood-brain barrier penetration: Are we missing the point? Drug Discov Today 9:161-162.
185. Pardridge WM. 2004. Log(BB), PS products and in-silico models of drug brain penetration. Drug Discov Today 9:392-393.
186. Clark DE. 2003. In-silico prediction of blood-brain barrier permeation. Drug Discov Today 8:927-933.
187. Good AC, Hermsmeier MA. 2007. Measuring CAMD technique performance. 2. How drug-like are drugs? Implications of random test set selection exemplified using druglikeness classification models. J Chem Inf Model 47:110-114.
188. Abraham MH, Hersey A. 2006. In silico models to predict brain uptake. In: Taylor JB, Triggle DJ, editors. Comprehensive Medicinal Chemistry II, Vol.5. Oxford: Elsevier Ltd. p. 745-766.
189. Abraham MH, Ibrahim A, Zhao YH, Acree WE Jr. 2006. A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J Pharm Sci 95:2091-2100. (Pubitemid 44568521)
190. Van de Waterbeemd H, Gifford E. 2003. ADMET in-silico modelling: Towards prediction paradise? Nat Rev Drug Discov 2:192-204.
191. Adenot M, Lahana R. 2004. Blood-brain barrier permeation models: Discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J Chem Inf Comput Sci 44:239-248.
192. Garg P, Verma J. 2006. In-silico prediction of blood-brain barrier permeability: An artificial neural network model. J Chem Inf Model 46: 289-297. (Pubitemid 43282122)
193. Goodwin JT, Clark DE. 2005. In-silico predictions of blood-brain barrier penetration: Considerations to 'keep in mind'. J Pharm Exp Therap 315:477-483.
194. Konovalov DA, Coomans D, Deconinck E, Heyden YV. 2007. Benchmarking of QSAR models for blood-brain barrier permeation. J Chem Inf Model 47:1648-1656. (Pubitemid 47210068)
195. Zhao YH, Abraham MH, Ibrahim A, Fish PV, Cole S, Lewis ML, de Groot MJ, Reynolds DP. 2007. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes. J Chem Inf Model 47:170-175. (Pubitemid 46225573)
196. Crivori P, Cruciani G, Carrupt PA, Testa B. 2000. Predicting blood-brain barrier permeation from three dimensional molecular structure. J Med Chem 43:2204-2216. (Pubitemid 30354545)
197. Kingsley N, Gillet V, Howe T, Oyarzabal J. 2005. Prioritizing compounds targeted to CNS disorders by using MARS approach, Presentation at 4th Symposium on Drug Discovery, Antwerp, Belgium.
198. Hitchcock SA, Pennington LD. 2006. Structurebrain exposure relationships. J Med Chem 49:7559-7583.
199. Overton E. 1899. On the general osmotic properties of the cell, their probable origin, and their significance for physiology. Vierteljahrsschr Naturforsch Ges Zuerich 44:88-135.
200. Soloway AH. 1958. Correlation of drug penetration of brain and chemical structure. Science 128:1572-1574.
201. Hansch C, Björkroth JP, Leo A. 1987. Hydrophobicity and central nervous system agents: On the principle of minimal hydrophobicity in drug design. J Pharm Sci 76:663-687. (Pubitemid 18026974)
202. Glave WR, Hansch C. 1972. Relationship between lipophilic character and anaesthetic activity. J Pharm Sci 61:589-591.
203. Abraham MH. 2004. The factors that influence permeation across the blood-brain barrier. Eur J Med Chem 39:235-240. (Pubitemid 38393750)
204. Gupta SP. 1989. QSAR studies on drugs acting at the central nervous system. Chem Rev 89:1765-1800.
205. Lipinski CA. 2004. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 1:337-341.
206. Lipinski CA, Hopkins A. 2004. Navigating chemical space for biology and medicine. Nature 432:855-861. (Pubitemid 40037141)
207. Lipinski CA. 2000. Drug-like properties and the causes for poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249.
208. Young RC, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, Jones M, Rana KK, Saunders D, Smith IR, Sore NE, Wilks TJ. 1988. Development of new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem 31:656-671. (Pubitemid 18070588)
209. Seiler P. 1974. Interconversion of lipophilicities from hydrocarbon/water systems into the octanol/water system. Eur J Med Chem 9:473-479.
210. Goodwin JT, Conradi RA, Ho NFH, Burton PS. 2001. Physicochemical determinants of passive membrane permeability: Role of solute hydrogen-bonding potential and volume. J Med Chem 44:3721-3729.
211. Clark DE. 1999. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 88:815-821. (Pubitemid 29398551)
212. Caron G, Ermondi G. 2005. Calculating virtual logP in the alkane/water system and its derived parameters and . J Med Chem 48:3269-3279.
213. Gratton JA, Abraham M, Bradbury MW, Chadha HS. 1997. Molecular factors influencing drug transfer across the blood-brain barrier. J Pharm Pharmacol 49:1211-1216. (Pubitemid 28022220)
214. Atkinson F, Cole S, Green C, van de Waterbeemd H. 2002. Lipophilicity and other parameters affecting brain penetration. Curr Med Chem Cent Nerv Syst Agent 2:229-240. (Pubitemid 36267727)
215. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. 1998. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6:151-165. (Pubitemid 29033982)
216. Norinder U, Haeberlein M. 2002. Computational Approaches to the prediction of blood-brain distribution. Adv Drug Deliv Rev 54:291-313. (Pubitemid 34260955)
217. Kelder J, Grootenhuis PDJ, Bayada DM, Delbressine LPC, Ploemen JP. 1999. Polar molecular surface area as dominating determinant for oral absorption and brain permeation of drugs. Pharm Res 16:1514-1519. (Pubitemid 29510546)
218. Rishton GM, LaBonte K, Williams AJ, Kassam K, Kolovanov E. 2006. Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr Opin Drug Discov Dev 9:303-313. (Pubitemid 43774159)
219. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623.
220. Fischer H, Gottschlich R, Seelig A. 1998. Blood-brain barrier permeation: Molecular parameters governing passive diffusion. J Membr Biol 165:201-211. (Pubitemid 28465226)
221. Gerebtzoff G, Seelig A. 2006. In-silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J Chem Inf Model 46:2638-2650. (Pubitemid 46008134)
222. Wichmann K, Diedenhofen M, Klamt A. 2007. Prediction of blood-brain partitioning and human serum albumin binding based on COSMO-RS smoments. J Chem Inf Model 47:228-233. (Pubitemid 46225578)
223. Kaznessis YN, Snow ME, Blankey JC. 2001. Prediction of blood-brain partitioning using Monte-Carlo simulations of molecules in water. J Comput Aided Mol Des 15:697-708.
224. Lombardo F, Blake JF, Curatolo WJ. 1996. Computation of brain-blood partitioning of organic solutes via free energy calculations. J Med Chem 39:4750-4755. (Pubitemid 26423893)
225. Keserü GM, Molnár L. 2001. High-throughput prediction of blood-brain partitioning: A thermodynamic approach. J Chem Inf Comput Sci 41:120-128. (Pubitemid 33645681)
226. Abraham MH. 2003. Can we identify models for intestinal absorption, blood brain barrier distribution and intestinal absorption? In: Ford M, Livingstone D, Dearden J, van de Waterbeemd H, editors. EuroQSAR 2002. Designing drugs and crop protectants: Processes, problems and solutions. Oxford: Blackwell. pp. 5-7.
227. Hutter MC. 2003. Prediction of blood-brain barrier permeation using quantum chemically erived information. J Comput Aided Mol Des 17:415-433.
228. Urbano-Cuadrado M, Luque-Ruiz I, Gómez-Nieto MA. 2007. QSAR models based on isomorphic and nonisomorphic data fusion for predicting the blood brain barrier permeability. J Comput Chem 28:1252-1260.
229. Li H, Yap CW, Ung CY, Xue Y, Cao ZW, Chen YZ. 2005. Effect of selection of molecular descriptors on the prediction of blood-brain barrier penetrating and nonpenetrating agents by statistical learning methods. J Chem Inf Model 45:1376-1384. (Pubitemid 41476020)
230. Deconinck E, Zhang MH, Coomans D, Heyden YV. 2006. Classification tree models for the prediction of blood-brain barrier passage of drugs. J Chem Inf Model 46:1410-1419. (Pubitemid 43999185)
231. Narayanan R, Gunturi SB. 2005. In-silico ADME modelling: Prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg Med Chem 13:3017-3028. (Pubitemid 40392479)
232. Cruciani G, Pastor M, Guba WA. 2000. New tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2:S29-S39. (Pubitemid 30734415)
233. Ooms F, Weber P, Carrupt PA, Testa B. 2002. A simple model to predict blood-brain barrier permeation from 3D molecular fields. Biochim Biophys Acta 1587:118-125. (Pubitemid 34655781)
234. Labute P. 2000. A widely applicable set of descriptors. J Mol Graph Model 18:464-477.
235. Klon AE, Lowrie JF, Diller DJ. 2006. Improve Naïve bayesian modeling of numerical data for absorption, distribution and excretion (ADME) property prediction. J Chem Inf Model 46:1945-1956.
236. Iyer M, Mishra R, Han Y, Hopfinger AJ. 2002. Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis. Pharm Res 19:1611-1621. (Pubitemid 35305512)
237. Pan D, Iyer M, Liu J, Li Y, Hopfinger AJ. 2004. Constructing Optimum Blood Brain Barrier QSAR Models Using a Combination of 4D-Molecular Similarity Measures and Cluster Analysis. J Chem Inf Comput Sci 44:2083-2098.
238. Winkler DA, Burden FR. 2004. Modelling blood-brain barrier partitioning using Bayesian neural nets. J Mol Graph Model 22:499-505. (Pubitemid 38746575)
239. Lobell M, Molnár L, Keserü GM. 2003. Recent advances in the prediction of blood-brain partitioning from molecular structure. J Pharm Sci 92:360-370. (Pubitemid 36169308)
240. Kaliszan R, Markuszewski M. 1996. Brain/blood distribution described by a combination of partition coefficient and molecular mass. Int J Pharm 145:9-16. (Pubitemid 27062981)
241. Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, Butina D. 2001. Correlation and prediction of a large blood-brain distribution data set - An LFER study. Eur J Med Chem 36:719-730. (Pubitemid 32973863)
242. Liu R, Sun H, So SS. 2001. Development of quantitative structure property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier penetration. J Chem Inf Comput Sci 41:1623-1632. (Pubitemid 33649774)
243. Cabrera MA, Bermejo M, Pérez M, Ramos R. 2004. TOPS-MODE approach for the prediction of blood-brain barrier permeation. J Pharm Sci 93:1701-1717. (Pubitemid 38823699)
244. Abraham MH, Ibrahim A, Acree WE Jr. 2005. Air to blood distribution of volatile organic compounds: A linear free energy analysis. Chem Res Toxicol 18:904-911. (Pubitemid 40705458)
245. Abraham MH, Ibrahim A, Acree WE Jr. 2006. Air to brain, blood to brain and plasma to brain distribution of volatile organic compounds: Linear free energy analyses. Eur J Med Chem 41:494-502. (Pubitemid 43939059)
246. Norinder U, Sjoberg P, Osterberg T. 1998. Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. J Pharm Sci 87:952-959. (Pubitemid 28381252)
247. Luco JM. 1999. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least squares (PLS) modeling. J Chem Inf Comput Sci 39:396-404.
248. Cruciani G, Crivori P, Carrupt PA, Testa B. 2000. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach. J Mol Struct (Theochem) 503:17-30.
249. Österberg T, Norinder U. 2000. Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics. J Chem Inf Comput Sci 40:1408-1411.
250. Norinder U, Österberg T. 2001. Theoretical calculation and prediction of drug transport processes using simple parameters and partial least squares projections to latent structures (PLS) statistics. The use of electrotopological state indices. J Pharm Sci 90:1076-1085.
251. Stanton DT, Mattioni BE, Knittel JJ, Jurs PC. 2004. Development and use of hydrophobic surface area (HSA) descriptors for computer-assisted quantitative structure-activity and structure-property relationship studies. J Chem Inf Comput Sci 44:1010-1023.
252. Sun H. 2004. A universal molecular descriptor system for prediction of log P, log S, log BB, and absorption. J Chem Inf Comput Sci 44:748-757.
253. Guyon I, Weston J, Barnhill S, Vapnik V. 2002. Gene selection for cancer classification using support vector machines. Mach Learn 46:389-422. (Pubitemid 34129977)
254. Degroeve S, De Baets B, Van de Peer Y, Rouzé P. 2002. Feature subset selection for splice site prediction. Bioinformatics 18:S75-S83. (Pubitemid 41073221)
255. Subramanian G, Kitchen DB. 2003. Computational models to predict blood-brain barrier permeation and CNS activity. J Comput Aided Mol Des 17:643-664. (Pubitemid 38344468)
256. CODESSA-PRO User's Manual, http://www.codessapro.com/manual/manual.htm.
257. Katritzky AR, Mu L, Lobanov VS, Karelson M. 1996. Correlation of boiling points with molecular structure. 1. A training set of 298 diverse organics and a test set of 9 simple inorganics. J Phys Chem 100:10400-10407. (Pubitemid 126789368)
258. Karelson M. 2000. Molecular descriptors in QSAR/QSPR. New York: Wiley-Interscience.
259. Devillers J, Balaban AT. 1999. Topological indices and related descriptors in QSAR and QSPR. The Netherlands: Gordon and Breach.
260. Todeschini R, Consonni V. 2000. Handbook of molecular descriptors. New York: Wiley-VCH.
261. Katritzky AR, Kuanar M, Slavov S, Dobchev DR. 2006. Correlation of blood-brain penetration using structural descriptors. Bioorg Med Chem 14:4888-4917. (Pubitemid 43786380)
262. Yap CW, Chen YZ. 2005. Quantitative structure - Pharmacokinetic relationships for drug distribution properties by using general regression neural network. J Pharm Sci 94:153-168.
263. Vapnik VN. 1995. The nature of statistical learning theory. New York: Springer.
264. Doniger S, Hofman T, Yeh J. 2002. Predicting CNS permeability of drug molecules: Comparison of neural network and support vector machine algorithms. J Comput Biol 9:849-864. (Pubitemid 36207918)
265. Trotter MW, Buxton BF, Holden SB. 2001. Support vector machines in combinatorial chemistry. Meas Control 34:235-239. (Pubitemid 32991937)
266. Obrezanova O, Csányi G, Gola JMR, Segall MD. 2007. Gaussian processes: A method for automatic QSAR modelling of ADME properties. J Chem Inf Model 47:1847-1857. (Pubitemid 47561132)
267. Guha R, Dutta D, Jurs PC, Chen T. 2006. Local lazy regression: Making use of the neighborhood to improve QSAR predictions. J Chem Inf Model 46:1836-1847. (Pubitemid 44185708)
268. Birattari M, Bontempi G, Bersini H. 1999. Lazy learning meets the recursive least squares algorithm. In: Advances in neural information processing systems 11. Cambridge, MA: MIT Press. pp. 375-381.
269. Bontempi G, Birattari M, Bersini H. 1999. Local learning for iterated time-series prediction. In: International conference on machine learning, Publisher: Place of Publication.
270. Aha D, Kibler D, Albert M. 1991. Instance-based learning algorithms. Mach Learn 6:37-66.
271. Glick M, Klon AE, Acklin P, Davies JW. 2004. Enriching extremely noisy high-throughput screening data using a naïve bayes classifier. J Biomol Screen 9:32-36. (Pubitemid 40503565)
272. Cramer RD III, Redl G, Berkoff CE. 1974. Substructural analysis. A novel approach to the problem of drug design. J Med Chem 17:533-535.
273. Hou TJ, Xu XJ. 2003. ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors. J Chem Inf Comput Sci 43:2137-2152.
274. Ajay Bemis GW, Murcko MA. 1999. Designing libraries with CNS activity. J Med Chem 42:4942-4951.
275. Kang YS, Terasaki T, Tsuji A. 1990. Acidic drug transport in-vivo through the blood-brain barrier: A role of the transport carrier for monocarboxylic acids. J Pharmacobiodyn 13:158-163. (Pubitemid 20165387)
276. Tsuji A. 2005. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2:54-62. (Pubitemid 40128026)
277. Cornford EM, Oldendorf WH. 1975. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta 394:210-211.
278. Pardridge WM, Yoshikawa T, Kang YS, Miller LP. 1994. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Phamacol Exp Ther 268:14-18. (Pubitemid 24039062)
279. Li JY, Boado RJ, Pardridge WM. 2001. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na+ nucleoside cotransporter CNT2. J Cereb Blood Flow Metab 21:929-936.
280. Pardridge WM. 2003. Blood-brain barrier drug targeting: The future of brain drug development. Mol Interv 3:90-105.
281. Pardridge WM. 2005. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2:3-14. (Pubitemid 40128022)
282. Allen DD, Lockman PR. 2003. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci 73:1609-1615. (Pubitemid 36869002)
283. Geldenhuys WJ, Lockman PR, McAfee JH, Fitzpatrick KT, Van der Schyf CJ, Allen DD. 2004. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg Med Chem Lett 14:3085-3092.
284. Geldenhuys WJ, Lockman PR, Nguyen TH, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD. 2005. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. Bioorg Med Chem Lett 15:4253-4261.
285. Chang C, Ray A, Swaan P. 2005. In-silico strategies for modeling membrane transporter function. Drug Discov Today 10:663-671. (Pubitemid 40704774)
286. Allen DD, Geldenhuys WJ. 2006. Molecular modelling of blood-brain barrier nutrient transporters: In-silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci 78:1029-1033.
287. Klepper J, Salas-Burgos A, Gertsen E, Fischbarg J. 2005. Bench meets bedside: A 10-year-old girl and amino acid residue glycine 75 of the facilitative glucose transporter Glut1. Biochemistry 44:12621-12626. (Pubitemid 41377303)
288. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. 1999. Selective expression of the large neutral aminoacid transporter at the blood-brain barrier. Proc Natl Acad Sci 12:12079-12084. (Pubitemid 29502861)
289. Pardridge WM. 2003. Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. Curr Opin Drug Discov Dev 6:683-691.
290. Pardridge WM. Brain drug targeting and gene technologies. Jpn J Pharmacol 87:97-103.
291. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L. 2007. Modelling of the blood-brain barrier in drug discovery and development. Nature Rev Drug Discov 6:650-661. (Pubitemid 47202487)
292. Löscher W, Potschka H. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98. (Pubitemid 40128029)
293. Löscher W, Potschka H. 2005. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76. (Pubitemid 41033402)
294. El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. 2004. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds. Implications for pharmacokinetics of selected substrates. Pharm Pharmacol 56:967-975.
295. Golden PL, Pollack GM. 2003. Blood-brain barrier efflux transport. J Pharm Sci 92:1739-1753.
296. Seelig A, Landwojtowicz E. 2000. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40. (Pubitemid 30838442)
297. Wiese M, Pajeva IK. 2001. Structure-activity relationships of multidrug resistance reservers. Curr Med Chem 8:685-713. (Pubitemid 32409800)
298. Avendaño C, Menendez JC. 2002. Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9:159-193. (Pubitemid 34436440)
299. Pleban K, Ecker GF. 2005. Inhibitors of P-glycoprotein - Lead identification and optimization. Mini Rev Med Chem 5:153-163. (Pubitemid 40305727)
300. Terasaki T, Hosoya K. 1999. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 36:195-209. (Pubitemid 29121972)
301. Ekins S. 2004. Predicting undesirable drug interactions with promiscuous proteins in-silico. Drug Discov Today 9:276-285. (Pubitemid 38328514)
302. Recanatini M, Bottegoni G, Cavalli A. 2004. Insilico antitarget screening. Drug Discov Today Technol 1:209-215.
303. Didziapetris R, Japertas P, Avdeef A, Petrauskas A. 2003. Classificatino analysis of P-glycoprotein substrate specificity. J Drug Target 11:391-406. (Pubitemid 38455825)
304. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PDJ. 2002. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45:1737-1740. (Pubitemid 34415368)
305. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen YZ. 2004. Prediction of P-glycoprotein substrates by a support vector machine approach. J Chem Inf Comput Sci 44:1497-1505. (Pubitemid 38660260)
306. Oyarzabal J, Pastor J. 2004. MARS approach for drug discovery: Aiding decision-making in in-silico ADME EuroQSAR. 15th European Symposium on Structure-Activity Relationships (QSAR) and Molecular Modelling, 219-220.
307. Li WX, Li L, Eksterowicz J, Ling XB, Cardozo M. 2007. Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates. J Chem Inf Model 47:2429-2438. (Pubitemid 350275107)
308. Pardridge WM. 2002. Drug and gene targeting to the brain with molecular Trojan horses. Nature Drug Discov Rev 1:131-139.
309. Pardridge WM, Boado RJ. 2008. Agents capable of crossing blood-brain barrier by receptor-mediated transport for diagnosis and treatment of brain disorders. Patent, PCT Int. Appl. 154pp. WO 2008022349 A2.
310. Pardridge WM. 2006. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 6:494-500. (Pubitemid 44348531)
311. Pardridge WM. 2007. Drug targeting to the brain. Pharm Res 24:1733-1744.
312. Pardridge WM. 2008. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconj Chem 19:1327-1338.
313. Engkvist O, Wrede P, Rester U. 2003. Prediction of CNS activity of compound libraries using substructure analysis. J Chem Inf Comput Sci 43:155-160.
314. Andres C, Hutter MC. 2006. CNS permeability of drugs predicted by a decision tree. QSAR Comb Sci 25:305-309.
315. Hou T, Xu X. 2002. ADME evaluation in drug discovery. J Mol Model 8:337-349.
316. Francis K, van Beek J, Canova C, Neal JW, Gasque P. 2003. Innate immunity and brain inflammation: the key role of complement. Exp Rev Mol Med 5:1-19.